Criteria | ACA | Not ACA | p | Anti-topo I | Not Anti-topo I | p | Anti-RNP | Not Anti-RNP | p | Anti-Th/To | Not Anti-Th/To | p |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Telangiectasia | 63 | 42 | < 0.01 | 56 | 53 | 0.8 | 7 | 57 | < 0.01 | 64 | 52 | 0.4 |
Calcinosis | 24 | 15 | 0.13 | 31 | 18 | 0.3 | 0 | 21 | 0.05 | 21 | 19 | 0.7 |
Arthritis | 29 | 41 | 0.12 | 31 | 35 | 1.0 | 40 | 34 | 0.8 | 50 | 33 | 0.2 |
Esophageal involvement | 52 | 41 | 0.14 | 50 | 46 | 0.8 | 13 | 49 | 0.01 | 43 | 46 | 1.0 |
Pulmonary fibrosis | 7 | 17 | 0.04 | 38 | 9 | < 0.01 | 7 | 12 | 1.0 | 21 | 11 | 0.2 |
FVC/DLCO > 1.4 | 61 | 45 | 0.05 | 56 | 53 | 0.8 | 42 | 54 | 0.6 | 54 | 53 | 1.0 |
Pulmonary artery pressure > 30 mm Hg | 9 | 6 | 0.6 | 0 | 8 | 0.6 | 0 | 8 | 0.6 | 8 | 7 | 1.0 |
ACA: anticentromere antibodies; FVC: forced vital capacity; DLCO: diffusing lung capacity for carbon monoxide.